What biochemical and molecular biological factors have greater relevance to treatment decisions?

Multidisciplinary Management of Rectal Cancer: Questions and Answers

Volumn 9783642250057, Issue , 2012, Pages 41-48

  Lammering, Guido ^a   Buijsen, Jeroen ^a  

^a MAASTRO CLINIC   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84949177202     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-25005-7_5     Document Type: Chapter

References (32)

1. Adelstein BA, Dobbins TA, Harris CA et al (2011) A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in meta-static colorectal cancer. Eur J Cancer. Jun;47(9): 1343-1354
2. Bosset JF, Collette L, Calais G et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114-1123
3. Bujko K, Glynne-Jones R, Bujko M (2010) Adjuvant chemotherapy for rectal cancer. Ann Oncol. Dec;21(12):2443
4. Grimminger PP (2010) XRCC1 gene polymorphism for prediction of response and prognosis in the multi-modality therapy of patients with locally advanced rectal cancer. J Surg Res 164:e61-e66
5. Hutchins G, Southward K, Handley K et al (2011) Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and bene fits from chemotherapy in colorectal cancer. J Clin Oncol 2011(29):1261-1270
6. Kapiteijn E, Marijnen CA, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638-646
7. Kim K, Chie EK, Wu HG et al (2011) High survivin expression as a predictor of poor response to preop-erative chemoradiotherapy in locally advanced rectal cancer. Int J Colorectal Dis. Aug;26(8):1019-1023
8. Koeberle D, Burkhard R, von Moos R et al (2008) Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer 98:1204-1209
9. Kuremsky JG (2009) Biomarkers for response to neo-adjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 74:673-688
10. Lamas MJ, Duran G, Gomez A et al (2012) X-ray cross-complementing group 1 and thymidylate syn-thase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients. Int J Radiat Oncol Biol Phys. Jan 1;82(1):138-144
11. Lammering G (2005) Molecular predictor and promising target: will EGFR now become a star in radiotherapy? Radiother Oncol 74:89-91
12. Lange MM, Maas CP, Marijnen CA et al (2008) Urinary dysfunction after rectal cancer treatment is mainly caused by surgery. Br J Surg 95:1020-1028
13. Leong KJ, Wei W, Tannahill LA et al (2011) Methylation pro filing of rectal cancer identi fies novel markers of early-stage disease. Br J Surg 98:724-734
14. Maas M, Beets-Tan RG, Lambregts DM et al (2011) Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. Dec 10;29(35):4633-4640
15. Marijnen CA, Nagtegaal ID, Klein Kranenbarg E et al (2001) No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 19:1976-1984
16. McDowell MT (2009) Increased spontaneous apopto-sis, but not survivin expression, is associated with histomorphologic response to neoadjuvant chemora-diation in rectal cancer. Int J Colorectal Dis 24: 1261-1269
17. Páez D et al (2011) Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradio-therapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes. Int J Radiat Oncol Biol Phys 81:1319-1327, Epub 2011 May 11
18. Peeters KC, van de Velde CJ, Leer JW et al (2005) Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients-a Dutch colorectal cancer group study. J Clin Oncol 23:6199-6206
19. Pettersson D, Cedermark B, Holm T et al (2010) Interim analysis of the Stockholm III trial of preoper-ative radiotherapy regimens for rectal cancer. Br J Surg 97:580-587
20. Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609-618
21. Pucciarelli S, Del Bianco P, Efficace F et al (2011) Patient-reported outcomes after neoadjuvant chemo-radiotherapy for rectal cancer: a multicenter prospective observational study. Ann Surg 253:71-77
22. Radu C, Berglund A, Påhlman L et al (2008) Short-course preoperative radiotherapy with delayed surgery in rectal cancer-a retrospective study. Radiother Oncol 87:343-349
23. Rasheed S, Harris AL, Tekkis PP et al (2009) Assessment of microvessel density and carbonic anhy-drase-9 (CA-9) expression in rectal cancer. Pathol Res Pract 205:1-9
24. Roth AD, Tejpar S, Delorenzi M et al (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. Jan 20;28(3):466-474. Epub 2009 Dec 14
25. Rödel F (2002) High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemo-therapy and surgical resection. Strahlenther Onkol 178:426-435
26. Rutten HJ, den Dulk M, Lemmens VE et al (2008) Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol 9:494-501
27. Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731-1740
28. Stephens RJ, Thompson LC, Quirke P et al (2010) Impact of short-course preoperative radiotherapy for rectal cancer patients' quality of life: data from the medical research council CR07/national cancer institute of Canada clinical trials group C016 randomized clinical trial. J Clin Oncol 28:4233-4239
29. Swellengrebel HA, Marijnen CA, Verwaal VJ et al (2011) Toxicity and complications of preoperative chemoradiotherapy for locally advanced rectal cancer. Br J Surg 98:418-426
30. Tol J, Dijkstra JR, Vink-Börger ME, et al (2010) High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med. Aug;14(8):2122-2131
31. Tan BR (2011) Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. J Clin Oncol 29: 875-883
32. Valentini V, Van Stiphout RGPM, Lammering G et al (2011) Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 29:3163-3172